Fournié-Zaluski MC[au] - Search Results

Year	Number of Results
1976	1
1977	1
1978	2
1979	4
1980	5
1981	5
1982	5
1983	4
1984	5
1985	6
1986	11
1987	3
1988	3
1989	10
1990	3
1991	4
1992	18
1993	8
1994	14
1995	11
1996	13
1997	9
1998	10
1999	12
2000	6
2001	7
2002	5
2003	7
2004	6
2005	2
2006	2
2007	2
2008	3
2009	5
2010	3
2011	1
2012	4
2013	2
2014	1
2015	2
2016	2
2017	2
2022	0

1

Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Roques BP, Fournié-Zaluski MC, Wurm M. Roques BP, et al. Among authors: fournie zaluski mc. Nat Rev Drug Discov. 2012 Apr;11(4):292-310. doi: 10.1038/nrd3673. Nat Rev Drug Discov. 2012. PMID: 22460123 Review.

2

Inhibitors of neprilysin: design, pharmacological and clinical applications.

Roques BP, Noble F, Crine P, Fournié-Zaluski MC. Roques BP, et al. Among authors: fournie zaluski mc. Methods Enzymol. 1995;248:263-83. doi: 10.1016/0076-6879(95)48019-6. Methods Enzymol. 1995. PMID: 7674926 Review. No abstract available.

3

Substituted α-mercaptoketones, new types of specific neprilysin inhibitors.

Poras H, Patouret R, Leiris S, Ouimet T, Fournié-Zaluski MC, Roques BP. Poras H, et al. Among authors: fournie zaluski mc. Bioorg Med Chem Lett. 2017 Aug 15;27(16):3883-3890. doi: 10.1016/j.bmcl.2017.06.050. Epub 2017 Jun 21. Bioorg Med Chem Lett. 2017. PMID: 28676269

4

Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.

Fournie-Zaluski MC, Coric P, Thery V, Gonzalez W, Meudal H, Turcaud S, Michel JB, Roques BP. Fournie-Zaluski MC, et al. J Med Chem. 1996 Jun 21;39(13):2594-608. doi: 10.1021/jm950783c. J Med Chem. 1996. PMID: 8691458

5

Mechanism of action of clostridial neurotoxins and rational inhibitor design.

Roques BP, Anne C, Turcaud S, Fournié-Zaluski MC. Roques BP, et al. Among authors: fournie zaluski mc. Biol Cell. 2000 Sep;92(6):445-7. doi: 10.1016/s0248-4900(00)01098-4. Biol Cell. 2000. PMID: 11132706 Review. No abstract available.

6

Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology.

Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, Beaumont A. Roques BP, et al. Among authors: fournie zaluski mc. Pharmacol Rev. 1993 Mar;45(1):87-146. Pharmacol Rev. 1993. PMID: 8475170 Review. No abstract available.

7

Angiotensin III: a central regulator of vasopressin release and blood pressure.

Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Reaux A, et al. Among authors: fournie zaluski mc. Trends Endocrinol Metab. 2001 May-Jun;12(4):157-62. doi: 10.1016/s1043-2760(01)00381-2. Trends Endocrinol Metab. 2001. PMID: 11295571 Review.

8

Studies on the conformation, enzymatic degradation, pharmacological potency, and binding properties in brain tissue of cholecystokinin-8 and new related peptides.

Roques BP, Durieux C, Gacel G, Pélaprat D, Ruiz-Gayo M, Belleney J, Fellion E, Zajac JM, Fournié-Zaluski MC, Daugé V, et al. Roques BP, et al. Among authors: fournie zaluski mc. Ann N Y Acad Sci. 1985;448:61-75. doi: 10.1111/j.1749-6632.1985.tb29907.x. Ann N Y Acad Sci. 1985. PMID: 2992350 Review. No abstract available.

9

[New painkillers inhibiting the physiological breakdown of endogenous opioids].

Roques BP, Fournié-Zaluski MC, Wurm M. Roques BP, et al. Among authors: fournie zaluski mc. Med Sci (Paris). 2012 May;28(5):476-8. doi: 10.1051/medsci/2012285011. Epub 2012 May 30. Med Sci (Paris). 2012. PMID: 22643000 Free article. French. No abstract available.

10

Fluorescent enkephalin derivatives with biological activity.

Fournie-Zaluski MC, Gacel G, Roques BP, Senault B, Lecomte JM, Malfroy B, Swerts JP, Schwartz JC. Fournie-Zaluski MC, et al. Biochem Biophys Res Commun. 1978 Jul 14;83(1):300-5. doi: 10.1016/0006-291x(78)90431-x. Biochem Biophys Res Commun. 1978. PMID: 697818 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results